Incoming goods lab of the service provider among the best ten percent in the industry
- Independent audit with focus on regulatory requirements
- Benchmarking supports status quo and operational excellence strategy
- Network expansion promotes new methodological approaches
RAVENSBURG, Germany, April 07, 2022 / B3C newswire / -- Vetter, a global leading contract development and manufacturing organization (CDMO), successfully participated in a lab benchmarking with its incoming goods lab in the past year. The University of St. Gallen (HSG) participated in the project as a scientific partner. This educational institution not only offers a wealth of comparative data but is also familiar with the requirements of the authorities, for example, the FDA (US Food and Drug Administration). This independent review supports Vetter's strategy of operational excellence.
"Comparing ourselves with other companies in the industry is an excellent way for Vetter to review our own performance and derive valuable connecting points for our laboratory divisions," explained Dr. Anne Kuhlmann, Vice President Quality Control. Using a standardized questionnaire, key figures on quality, cost level, and productivity have been raised. HSG evaluated the data and then compared it with other companies in the industry.
Recently, the results of the benchmarking have been published: in terms of overall performance, Vetter is among the top ten percent of the industry. "The balanced performance result in the areas of effectiveness and efficiency is particularly noteworthy," said Gian-Andri Steiger, Research Associate at HSG. If the results in those two areas are in harmony, this indicates sustainably robust processes in the context of scientific benchmarking – while providing constantly high quality. "Vetter thus shows itself to be a stable and future-proof partner for its customers," said Steiger.
After the microbiology and chemical analysis departments had already taken part previously – with very good ratings as well – the audit of the incoming goods laboratory was the company’s third benchmarking with the University of St. Gallen. "The collaboration with HSG was very sound and profitable," said Dr. Kuhlmann. Another important outcome for Vetter: the network expansion of all benchmarking participants, including customers and competitors who take part in a monthly roundtable. This enables a quick and easy exchange on a variety of complex topics that affect the industry and enables continuous progress to be made together for the benefit of patients worldwide.
Caption: The laboratory teams use extensive, innovative analytical techniques to control all raw materials and auxiliaries used in the production chain.
© Vetter Pharma International GmbH
For high resolution please click the image.
Second picture
Caption: Thanks to sustainably robust processes, Vetter presents itself as a stable and future-proof partner for customers worldwide
© Vetter Pharma International GmbH
Find the Vetter press kit and more background information here:
About the University of St. Gallen (HSG)
For more than a hundred years, the HSG has been part of St. Gallen - in the beginning as a "commercial academy", today as a university. In accordance with the HSG's vision and its guiding principles, it is internationally recognized not only for its teaching but also for its research in selected areas. The HSG conducts problem-solving-oriented basic research on the one hand, and research-based teaching on the other. In doing so, it systematically exploits synergies with traditionally practice-focused research. As a respected research institution, it offers attractive research conditions to both young and experienced scientists, with targeted support for junior researchers.
About Vetter
Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 5,700 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability.
Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
+49 (0)751-3700-3729
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Pharmaceutical Services; Outsourced Services; Pharmaceutical Preparations; Laboratories; Drug Packaging; Drug Delivery Systems; Product Packaging; Commerce; Biological Products; Syringes; Biotechnology; Germany
Published by B3C newswire